Q1 2017 13F Holders as of 3/31/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
9.69M
-
Shares change
-
-144K
-
Total reported value, excl. options
-
$210M
-
Value change
-
-$3.15M
-
Number of buys
-
22
-
Number of sells
-
-12
-
Price
-
$21.76
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q1 2017
44 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q1 2017.
CRISPR Therapeutics AG - Common Stock (CRSP) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.69M shares
of 86M outstanding shares and own 11.27% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (3.22M shares), Abingworth LLP (2.6M shares), Clough Capital Partners L P (825K shares), WELLINGTON MANAGEMENT GROUP LLP (747K shares), FRANKLIN RESOURCES INC (729K shares), New Leaf Venture Partners, L.L.C. (586K shares), ORBIMED ADVISORS LLC (372K shares), Novo A/S (223K shares), Vivo Capital, LLC (149K shares), and CREDIT SUISSE AG/ (80K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.